Does Radiotherapy for the Primary Tumor Benefit Prostate Cancer Patients with Distant Metastasis at Initial Diagnosis?

Yeona Cho¹, Jee Suk Chang¹, Koon Ho Rha², Sung Joon Hong², Young Deuk Choi², Won Sik Ham², Jun Won Kim¹, Jaeho Cho¹*

¹ Departments of Radiation Oncology, Yonsei University College of Medicine, Seoul, Korea, ² Department of Urology, Yonsei University College of Medicine, Seoul, Korea

* jjhmd@yuhs.ac

Abstract

Purpose/Objectives
Treatment of the primary tumor reportedly improves survival in several types of metastatic cancer. We herein evaluated the efficacy and toxicity of radiotherapy for the primary tumor in prostate cancer with metastasis.

Materials/Methods
The study cohort included 140 men with metastatic prostate cancer at initial diagnosis. Metastatic sites were divided into 4 groups as follows: solitary bone, 2–4 bones, ≥5 bones, and visceral organs. Patient, tumor, and treatment characteristics, and clinical outcomes were compared between patients treated with (prostate radiotherapy [PRT] group) or without radiotherapy to the primary tumor.

Results
Patients in PRT group presented with a statistically significantly younger age (p = .02), whereas other characteristics showed no significant difference. Overall survival (OS) and biochemical failure-free survival (BCFFS) were improved in PRT patients (3-year OS: 69% vs. 43%, p = 0.004; 3-year BCFFS: 52% vs. 16%, p = 0.002). Multivariate analysis identified PRT as a significant predictor of both OS (hazard ratio [HR] = 0.43, p = 0.015). None of the 38 PRT patients experienced severe (grade ≥3) genitourinary or gastrointestinal toxicity.

Conclusions
Our data suggest that radiotherapy to the primary tumor was associated with improved OS and BCFFS in metastatic prostate cancer. The results of this study warrant prospective controlled clinical trials of this approach in stage IV prostate cancer patients with limited extent of bone metastasis and good performance status.
Introduction

Aggressive treatment of the primary tumor is usually not recommended for patients with stage IV metastatic cancers. However, in certain types of malignancy, local treatment of the primary site with systemic therapy reportedly improves overall survival (OS) or enhances the efficacy of other therapeutics for the metastatic disease. In 1989, the Southwest Oncology Group initiated a randomized trial of nephrectomy in metastatic renal-cell cancer [1,2]. This study demonstrated that nephrectomy followed by interferon therapy resulted in longer survival among patients with metastatic renal-cell cancer than interferon therapy alone. In another trial, nephrectomy significantly improved the median OS from 7 to 17 months [3]. In 2004, Temple et al. reported that metastatic colon cancer patients undergoing primary tumor resection had a better response to chemotherapy [4]. Recent retrospective studies have shown that radiotherapy (RT) to or surgical excision of the primary tumor is associated with a better prognosis in patients with metastatic breast cancer [5,6]. Furthermore, the prognosis of stage IV metastatic diseases is relatively good in the above-mentioned cancer types. Even in advanced cancer, local treatment becomes more important as patient survival time increases because it can prevent subsequent distant seeding and relieve local symptoms due to progression of the primary site.

Similarly, prostate cancer patients with stage IV metastatic diseases also have a relatively good survival [7]. Hormonal therapy is the most commonly used first-line therapy for metastatic prostate cancer [8]. However, systemic therapy alone has resulted in a median survival of no more than 36 months in metastatic prostate cancer patients [9–11]. An intuitive argument is that in potentially metastatic cancer, the longer the primary tumor remains, the more metastatic events will occur [12]. Cytoreductive treatment via primary tumor radiotherapy may have a role in the management of metastatic prostate cancer.

Moreover, the systemic effect of RT, called the abscopal effect, has been explored in several studies [13,14]. The local inflammatory reactions generated by RT activate several immunological signals and contribute to better antigen cross-presentation leading to CD8+ cytotoxic T-cell activation. In other words, the signals induced by RT could convert the irradiated tumor into an immunogenic antigen and the host’s immune system response to the tumor can contribute both to the local response to RT and to a systemic rejection of metastasis [14].

In general, local treatment for the primary tumor includes surgery and radiotherapy. For prostate cancer, radiation therapy is less invasive with newly developed techniques to minimize side effects [15]. If the therapy is well tolerated with minimal side effects, more aggressive treatment to the primary tumor can be applied in metastatic diseases.

In the present study, we aimed to investigate the role of radiotherapy to the primary tumor in patients with prostate cancer presenting as M1 diseases, with an assumption that the natural course of the diseases could be improved if the primary tumors are treated locally together with systemic therapy.

Materials and Methods

Patient eligibility

We identified 3,578 consecutive men who were diagnosed with prostate cancer between 2003 and 2011 at our institution. All men presented with metastatic disease at initial diagnosis or within 1 month from the initial diagnosis were included. Patients with other primary malignancies or those who underwent prostatectomy before radiotherapy were excluded. The final study cohort of this study included 140 men. The American Joint Committee on Cancer (AJCC) stage was used to classify metastatic disease. Metastases to the pelvic lymph node (LN), including the obturator, iliac, sacral, and hypogastric LN were defined to be regional LN
metastases, and metastases beyond the pelvic cavity were classified as distant metastases, clinically M1 disease.

This study was approved by Institutional review board (IRB) of Yonsei University Health System (IRB protocol number 4-2014-0842). All data were collected by analyzing medical reports and information in our institutional medical records. However, due to the retrospective aspect of this study, patient informed consent was not provided for this study. But all subjects had provided written permission for their medical records to be used for research purposes as provided for.

Treatment type and indication

Of 140 eligible men in this study, 63 (45%) did not receive any radiotherapy. Among 77 patients (55%) who received radiotherapy, local radiotherapy to the primary tumor was performed in 38 patients (27%) (Fig 1A). In the present study, local treatment to the primary tumor was confined to radiotherapy delivered to the prostate, but not surgery. Radiotherapy was delivered to the prostate with pre-defined margins according to European Organisation for Research and Treatment of Cancer (EORTC) guideline [16], and metastatic lesions were treated to include gross tumor volume and appropriate margins (Fig 1B). Indication for radiotherapy to the prostate was decided based on the needs of patients with urinary symptoms and personalized at the discretion of the treating radiation oncologist. Systemic therapy, as indicated by the treating urologist or oncologist, might be given before radiotherapy and immediately after diagnosis. Indications for radiotherapy to metastatic lesions included pain, risk of fracture, and neurologic complications or disease control without any symptom. Most patients (96%) started androgen deprivation therapy at the time of initial diagnosis.

![Fig 1. Treatment scheme of all patients (A) and an example of the treatment for a patient receiving prostate radiotherapy (B).](http://example.com/fig1.png)

doi:10.1371/journal.pone.0147191.g001
Outcome and toxicity analysis

In this study, the primary endpoint was OS, and the secondary endpoints included biochemical failure-free survival (BCFFS). The Phoenix definition (nadir + 2 ng/mL) is commonly used due to several limitations of the previous ASTRO definition. However, the Phoenix definition also has limitations and a controversy still exists. We defined BCFFS as three consecutive increases in the prostate-specific antigen (PSA) level after nadir (ASTRO definition) for the following reasons. First, our patients had metastatic disease with more extensive lesions and their baseline PSA level was relatively higher (median 190 ng/mL, range 3.1–17800 ng/mL) than those without metastasis. Second, unless all tumors are cured, there are still residual tumors and the nadir PSA levels do not fall to subclinical levels (<4 ng/ml) in many patients. Third, patients treated with ADT frequently show PSA bounces [17] and a nadir + 2 ng/mL definition could result in more false-positive incidents in metastatic patients. In addition, the definition of castration-resistant prostate cancer is rising PSA levels or progressive disease in the setting of serum testosterone levels within the castrate range (< 50 ng/dl) [18]. Overall, considering these reasons, we thought the ASTRO definition is more applicable in metastatic cancer and we used the ASTRO definition in our study.

Toxicity monitoring was performed on patients receiving radiotherapy during all follow-up visits. Gastrointestinal (GI) or genitourinary (GU) toxicity was scored according to the Radiation Therapy Oncology Group and EORTC criteria. Hematologic toxicity was scored according to the Common Terminology Criteria for Adverse Events version 4.0. Each patient who received radiotherapy underwent weekly hematologic evaluation. The parameters included all hematologic abnormalities, GI or GU symptoms, and other adverse events reported by patients.

Statistical analysis

Two groups of patients were analyzed in this study: those whose primary tumor was treated with radiotherapy (the prostate radiotherapy [PRT] group) and those who did not receive radiotherapy to their primary tumor. Comparisons of patient and treatment characteristics between the two groups were performed using the chi-square and Fisher exact tests. The rates of OS and BCFFS were calculated by the Kaplan–Meier method. Statistical significance of survival differences was examined using the log-rank test. Cox’s regression model was used for multivariate analysis of OS. All significance was established at \( p < 0.05 \). All statistical analyses were performed using the SPSS software package, version 20.0.0 (SPSS Inc., Chicago, IL, USA).

Results

Patient and radiotherapy characteristics

Table 1 summarizes the clinical characteristics of the entire cohort and comparison between patients who received prostate radiotherapy and those who did not. The median age was 69 years, and 55% of the patients were \( \geq 70 \) years. The Eastern Cooperative Oncology Group (ECOG) performance status was 0–1 in 79% of patients; 74% had a Gleason score \( \geq 8 \); and the initial PSA levels were \( \geq 100 \) ng/mL in 61% of patients. The number of metastatic lesions on initial presentation was 1 in 13% of patients, 2–4 in 30%, and \( \geq 5 \) in 40%, with 78% of the cases being bone metastases. Age was the only factor with significant distribution difference between PRT and non-PRT patients, whereas no significant differences in the distribution of performance status, Gleason score at diagnosis, initial PSA level, disease extent, metastatic site, and the use and duration of androgen deprivation therapy were observed between the two groups.
All patients received conventional or hypo-fractionated radiotherapy with a median dose of 60 Gy in 24 fractions (fx) (varying from 30 Gy/10 fx-72.6 Gy/33 fx) to the prostate (1.8–4 Gy per fraction). Common radiation schedules were 70 Gy/28fx (BED$_3$ = 128.3 Gy) in 11 patients (29%) and 55 Gy/20fx (BED$_3$ = 105.4 Gy) in 10 patients (26%). No patients received stereotactic body radiotherapy. Metastatic lesions received a median dose of 40 Gy in 10 fractions (range 22.5–54 Gy). Fifty-five (71%) patients were treated with tomotherapy, while others received conventional 3D-conformal radiotherapy. The extent and site of radiotherapy in the PRT and palliative radiotherapy groups are described in Fig 2.

The median nadir PSA level was relatively lower in the PRT group (1.12 vs. 0.61 ng/mL, $p = 0.042$) and more patients in the PRT group showed subclinical PSA levels (nadir PSA <4 ng/mL) than those in the non-PRT group (87% vs.55%, $p = 0.002$) (Table 1).

### Survival

The median follow-up time was 34.0 months (range, 1.7–108.8 months) in the entire cohort. The 3-year OS of all patients was 48.2%, and BCFFS was 25%. The 3-year OS rate was higher in men receiving PRT than in those who did not (3-year OS: 69% vs. 43%, $p = 0.004$). Significantly

### Table 1. Characteristics of the entire patient cohort and comparisons between patients with and without prostate radiotherapy (PRT).

| Characteristic       | Entire cohort | PRT (−) | PRT (+) | p value |
|----------------------|--------------|---------|---------|---------|
|                      | N = 140     | N = 102 | N = 38  |         |
| N (%)                |             |         |         |         |
| Age (years)          |             |         |         |         |
| <70                  | 77 (55)     | 50 (49) | 27 (71) | 0.02    |
| ≥70                  | 63 (45)     | 52 (51) | 11 (29) |         |
| ECOG status          |             |         |         |         |
| 0–1                  | 111 (79)    | 77 (75) | 34 (89) | 0.099   |
| 2–3                  | 29 (21)     | 25 (25) | 4 (11)  |         |
| Histology            |             |         |         |         |
| Adenoca              | 136 (97)    | 96 (96) | 38 (100)| 0.216   |
| Others               | 4 (3)       | 4 (4)   | 0 (0)   |         |
| Type                 |             |         |         |         |
| Acinar               | 120 (86)    | 89 (87) | 31 (82) | 0.427   |
| Others               | 14 (10)     | 10 (10) | 4 (11)  |         |
| Unknown              | 6 (4)       | 3 (3)   | 3 (8)   |         |
| GS                   |             |         |         |         |
| ≥8                   | 104 (74)    | 79 (77) | 25 (66) | 0.122   |
| <8                   | 22 (16)     | 16 (16) | 6 (16)  |         |
| Unknown              | 14 (10)     | 7 (7)   | 7 (18)  |         |
| Hormonal therapy     |             |         |         |         |
| Yes                  | 136 (97)    | 98 (96) | 38 (100)| 0.213   |
| No                   | 4 (3)       | 4 (4)   | 0 (0)   |         |
| iPSA (ng/mL)         | Median      | 191.5   | 221.0   | 126.0   | 0.134   |
|                      | <100        | 54 (39) | 36 (35) | 18 (47) | 0.426   |
|                      | 100–200     | 17 (12) | 13 (13) | 4 (11)  |         |
|                      | >200        | 69 (49) | 53 (52) | 16 (42) |         |
| Number of metastases| 1           | 25 (13) | 13 (13) | 12 (32) | 0.642   |
|                      | 2–4         | 42 (30) | 30 (29) | 12 (32) |         |
|                      | ≥5          | 57 (40) | 46 (45) | 11 (29) |         |
| Metastasis           | Visceral + others | 32 (23) | 27 (26) | 5 (15)  | 0.126   |
|                      | Bone only   | 108 (77)| 75 (74) | 33 (85) |         |
| Nadir PSA (ng/mL)    | Median      | 1.11    | 1.12    | 0.61    | 0.042   |
|                      | Nadir PSA < 4 ng/mL | 89 (64) | 56 (55) | 33 (87) | 0.02    |

Abbreviations: PRT, prostate radiotherapy; ECOG, Eastern Cooperative Oncology Group; GS, Gleason score; iPSA, initial prostate-specific antigen.

doi:10.1371/journal.pone.0147191.t001
prolonged BCFFS was also observed in the PRT group (3-year BCFFS: 52% vs. 16%, \( p = 0.002 \)) (Fig 3A). Subgroup analysis was performed for the non-PRT patients. Of these, 39 patients received palliative radiotherapy to the metastatic sites with androgen deprivation treatment, whereas the others (\( n = 63 \)) received systemic therapy only. No significant differences in OS (3-year: 50% vs. 40%, \( p = 0.441 \)) and BCFFS (3-year 10% vs. 20%, \( p = 0.293 \)) were observed between patients receiving palliative radiotherapy and those who did not (Fig 3B).

### Prognostic factors

Univariate analysis revealed that ECOG performance status, metastatic site, disease extent, and PRT were significant factors for OS. Furthermore, multivariate analysis confirmed irradiation to the prostate as a significant predictor of both OS (hazard ratio [HR] = 0.5, \( p = 0.046 \)) (Table 2). For BCFFS, site of metastasis (bone vs. non-bone) and ECOG performance status scores (0–1 vs. 2–3), Gleason score and extent of disease did not show any significance (all \( p > 0.05 \)), except PRT (\( p < 0.001 \)) in univariate analysis.

### Toxicities in PRT group

None of the 38 patients in the PRT group experienced severe (grade \( \geq 3 \)) GU or GI toxicity. In this group, 4 patients (11%) had grade 3 thrombocytopenia, and 3 (8%) had grade 3...
leukocytopenia. Several patients received transfusion to prevent more severe adverse events, and most of the side effects were tolerable.

**Discussion**

Our results from this study indicated that radiotherapy for the primary tumor improved prognosis of patients with metastatic prostate cancer. Men who received radiotherapy to the primary tumor had a favorable OS compared to those who did not (3-year OS: 69% vs. 43%).
Such improvement of prognosis was observed not only in OS but also in BCFFS (3-year BCFFS: 52% vs. 16%, \( p = 0.002 \)). The effect of treatment was not significantly different among patients with various extent of metastasis. However, results of a stratified analysis suggested a greater effect among patients with only bone metastases at diagnosis and with good performance status.

Currently, radiotherapy for prostate cancer patients with distant metastasis is limited to palliative treatment to relieve local symptoms such as pain or urinary problems. Treatment of the primary tumor is often regarded inappropriate if metastasis is present. Moreover, Camphausen et al. revealed that the use of radiation to primary tumor resulted in the progression of previously dormant lung metastases by an imbalance of proangiogenic over antiangiogenic factors in mice model [19]. However, in our study, radiotherapy to the primary prostate tumor did not impair survival but improved overall survival. This finding is consistent with previously reported findings of other malignancies, such as renal cell cancer, colorectal cancer, and breast cancer, for which a local treatment of primary tumor is effective in improving patients survival [2–5].

There is biologic evidence to support our proposal to treat primary tumor in patients with distant metastasis. Extensive experimental models had confirmed Paget’s original “seed and soil” theory that hypothesize the organ-preference of metastasis formation is the result of interactions between circulating tumor cells (the “seed”) and organ microenvironment (the “soil”) [20]. Not only supplying the “seed,” the primary tumor also has a major role to prepare the “soil”. Kaplan et al. reported that the initial event at a metastatic site is not the arrival of circulating tumor cells, but the recruitment of bone marrow-derived cells (BMDCs) at the metastatic site. These BMDCs make the microenvironment of the metastatic organ more acceptable to colonization of tumor cells forming ‘pre-metastatic niche’ [21]. Such a finding implicates that therapy directed toward the primary tumor, by inhibiting the endocrine molecules secreted by primary tumor, could delay the formation and growth of distant metastases. Weckermann et al. also evaluated the disseminated tumor cells (DTCs) before and after prostatectomy by analyzing the cytokeratin-positive (CK+) cells in bone marrow since CK+ cells were regarded

### Table 2. Univariate and multivariate analyses of overall survival

| Characteristics          | Group   | No | Univariate analysis | Multivariate analysis |
|--------------------------|---------|----|---------------------|-----------------------|
|                          |         |    | 3-year rate (%)     | \( p \) value     | HR | \( p \) value |
| Age (years)              | <70     | 77 | 53                  | 0.075                |    |              |
|                          | ≥70     | 63 | 39                  |                      |    |              |
| ECOG status              | 0–1     | 111| 65                  | 0.004                | 1.57| 0.121       |
|                          | 2–3     | 29 | 23                  |                      |    |              |
| GS                       | <8      | 22 | 41                  | 0.758                |    |              |
|                          | ≥8      | 104| 54                  |                      |    |              |
| Metastasis site          | Bone only | 107| 52                  | 0.005                | 1.85| 0.058       |
|                          | Others  | 33 | 3                   |                      |    |              |
| Disease extent           | 1       | 25 | 57                  | 0.007                | 0.096|             |
|                          | 2–4     | 41 | 41                  |                      |    |              |
|                          | ≥5      | 66 | 28                  |                      |    |              |
|                          | Visceral| 8  | 0                   |                      |    |              |
| PRT (+)                  |         | 35 | 43                  | 0.012                | 0.43| 0.015       |
| PRT (-)                  |         | 105| 62                 |                      |    |              |

**Abbreviations**: PRT, prostate radiotherapy; ECOG, Eastern Cooperative Oncology Group; GS, Gleason score.

doi:10.1371/journal.pone.0147191.t002

\( p = 0.004 \).
as indicators of disseminated tumor cells (DTCs) [22]. They reported that DTCs before prostatectomy were significantly associated with an increased risk of metastases, but DTCs after surgery were not. This result suggested that the increased risk of metastasis manifested by DTCs was associated with an intact primary tumor and is consistent with the hypothesis that factors from the primary tumor are required to stimulate DTCs to colonize and grow.

A recent large-scale retrospective analysis also reports interesting findings. Positive pelvic lymph node is deemed to be a risk factor for distant metastasis and local therapy is in general omitted in favor of androgen-deprivation therapy. A study of the Munich Cancer Registry analyzed treatment outcomes in 938 prostate cancer patients with nodal metastases at the time of pelvic lymph node dissection [23]. Patients who underwent radical prostatectomy showed much favorable outcome compared to those who did not (10-year OS 64% vs. 28%). Although the group with radical prostatectomy had more favorable features, these findings showed at least a possible benefit from aggressive local treatment in patients with metastatic disease.

A possible hypothesis for treatment of the primary tumor could be the abscopal effect. However, this is less likely to happen after conventional fractionated RT alone, which may be insufficient to generate a systemic and robust antitumor effect. As initial treatment for metastatic prostate cancer or castration-resistant prostate cancer (CRPC), other systemic treatments as well as ADT could be administered. Docetaxel-based systemic chemotherapy has been generally used to treat metastatic prostate cancer after the approval of docetaxel in 2004 [24]. In addition, sipuleucel-T, an autologous prostatic acid phosphatase (PAP) directed cell-based immunotherapy product manufactured using patients’ own antigen-presenting cells, showed a survival benefit in a randomized phase III trial, and is recommended with category 1 evidence for patients who have a life expectancy of at least 3 months with a good performance status [25]. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) blockade via the monoclonal antibody ipilimumab also has attracted attention due to positive results in patients with metastatic melanoma and renal cell carcinoma, as well as several other malignancies [26]. Ipilimumab is also currently being evaluated in the prechemotherapy and postchemotherapy settings in men with metastatic CRPC. Further evidence of the efficacy of combined modalities for metastatic prostate cancer is needed so that systemic control and a radiation-induced immune response can be amplified sufficiently.

Another practical reason for us to suggest primary tumor radiotherapy for stage IV prostate cancer is that recently developed techniques have significantly reduced treatment-related side effects. In other words, addition of the primary tumor in the radiotherapy field does not cause patient discomfort. In this study, 71% of patients in the PRT group received intensity-modulated radiotherapy (IMRT) using helical tomotherapy and no patient experienced severe (grade ≥3) GI or GU toxicity. The IMRT is a newer radiotherapy technique that uses intensity-modulated beams to provide multiple intensities, allowing more concave dose distribution than conventional techniques. Furthermore, the chronic and acute toxicities associated with radiotherapy for prostate cancer are well documented [27]. In the era of IMRT, several studies have demonstrated the feasibility and efficacy of IMRT for prostate cancer in a large number of patients. Acute and late GI and GU toxicities seem to be significantly lower than those observed with conventional 3D-conformal radiotherapy techniques [15]. Moreover, IMRT using helical tomotherapy makes it possible to treat a wide range of lesions including the prostate and metastatic sites simultaneously. Compared to other local treatment such as prostatectomy. Based on a risk versus benefit analysis, radiotherapy with this less invasive and more effective treatment technique is suitable for prostate cancer patients with distant metastases, compared to other local treatments such as prostatectomy.

However, IMRT using helical tomotherapy could treat a wide range of metastatic lesion which is spreading vertical axes and most common acute side effect in PRT group was
thrombocytopenia and leukocytopenia. Previous report in our institution suggested that the
tolerance cutoff point of red marrow was 26.8% to avoid severe leukocytopenia (grade ≥3)
[28]. With this finding, we have taken into account for the proportion of bone marrow when
we treat wide range of bone metastasis.

In this study, good performance status, bone only metastasis and limited disease extent were
identified as prognostic factors for OS (ECOG PS 0–1 vs. 2–3, 3-yr OS 65% vs. 23%, p = 0.004;
bone only metastasis vs. others, 3-yr OS 52% vs. 3%, p = 0.005; disease extent, single metastasis
vs. 2–4 metastases vs. ≥5 metastases 3-yr OS 57% vs. 41% vs. 28%, respectively, p = 0.007). Our
results showing a better prognosis in patients with bone-only metastasis are consistent with
observations from a recent study of patients from the SEER database. This study reported that
men with visceral metastasis showed inferior OS to that of men with bone-only metastasis
[29]. These findings suggested that prostate may have several phenotypes that predispose to
different natural histories when survival represents the end point. While the underlying mecha-
nism of different survival outcome according to the metastatic site observed between studies
unclear, we emphasize that retrospective studies should be cautiously interpreted within their
limitations.

The association with limited disease extent and survival benefit in metastatic disease has
been studied in other tumors including breast cancer, renal cell carcinoma and colorectal can-
cer [4,30,31]. Nguyen et al. revealed that limited metastatic disease, defined as <5 metastatic
lesions is a favorable prognostic factor in stage IV breast cancer (5-yr OS 29.7% vs. 13.1%,
p <0.001). They also found that locoregional treatment for breast cancer improved overall sur-
vival (5-yr OS 35.5% vs. 20.4%, p = 0.01). These results are in accordance with our study. Prog-
nostic factors defined in this study could help the clinicians identify reasonable candidates for
radiotherapy to primary tumor and evaluate appropriate treatment strategies. Selected patients
with limited extent of bone metastasis in good performance status could obtain the maximum
benefit from this treatment strategy.

As the present investigation is not a randomized study, it is important to consider the possi-
bility of selection bias due to unrecorded factors. In such a case, the differences in mortality
risk observed between patients receiving PRT and those who did not could reflect the lower util-
ization of PRT in men with putative poorer disease prognosis. In addition, further evaluations
including metastatic markers or immunohistochemical staining results for understanding the
biologic behavior of tumors and metastatic sites are needed. Therefore the results of this pilot
study warrant a subsequent prospective randomized control trial to find out the effectiveness
of aggressive treatment to primary prostate gland in patients with stage IV prostate cancer. The
STAMPEDE (the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of
Drug Efficacy) trial from Medical Research Council Clinical Trials Unit (MRC CTU) was initi-
ated in 2013 and result from this trial could prove the benefit of PRT [32].

Conclusions

Radiotherapy including treatment of the primary tumor for prostate cancer patients with dis-
tant metastasis resulted in improved biochemical control and long-term survival. The results of
this study warrant a randomized controlled clinical trial to confirm these.

Author Contributions

Conceived and designed the experiments: YC JSC KHR SJH YDC WSH JWK JC. Performed
the experiments: YC JSC JWK JC. Analyzed the data: YC JSC JC. Contributed reagents/materials/
analysis tools: YC JSC KHR SJH YDC WSH. Wrote the paper: YC JSC KHR JC.
References

1. Adli M, Sevinc A, Kalender ME. Re: Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. 2006; 98: 364–365; author reply 365.

2. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001; 345: 1655–1659. PMID: 11796943

3. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R, European Organisation for R, et al. Radical nephrectomy plus interferon-alpha-based immunotherapy compared with interferon alpha alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001; 358: 966–970. PMID: 11583750

4. Temple LK, Hsieh L, Wong WD, Saltz L, Schrag D. Use of surgery among elderly patients with stage IV colorectal cancer. J Clin Oncol. 2004; 22: 3475–3484. PMID: 15337795

5. Nguyen DH, Truong PT, Alexander C, Walter K, Hayashi E, Christie J, et al. Can locoregional treatment of the primary tumor improve outcomes for women with stage IV breast cancer at diagnosis? Int J Radiat Oncol Biol Phys. 2012; 84: 39–45. doi: 10.1016/j.ijrobp.2011.11.046 PMID: 22330986

6. Rapiti E, Verkooijen HM, Vlastos G, Fioretta G, Neyroud-Caspar I, Sappino AP, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol. 2006; 24: 2743–2749. PMID: 16702580

7. Norgaard M, Jensen AO, Jacobsen JB, Cetin K, Fryzek JP, Sorensen HT. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol. 2010; 184: 162–167. doi: 10.1016/j.juro.2010.03.034 PMID: 20483155

8. Mohler JL, Armstrong AJ, Bahnson RR, Boston B, Busby JE, D’Amico AV, et al. Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012; 10: 1081–1087. PMID: 22956807

9. Glass TR, Tangen CM, Crawford ED, Thompson I. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol. 2003; 169: 164–169. PMID: 12478127

10. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, el al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364: 1995–2005. doi: 10.1056/NEJMoa1014618 PMID: 21612468

11. Lam JS, Lepper JT, Vemulapalli SN, Shvarts O, Belldegrun AS. Secondary hormonal therapy for advanced prostate cancer. J Urol. 2006; 175: 27–34. PMID: 16406864

12. Coen JJ, Zietman AL, Thakral H, Shippy WJ. Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases. J Clin Oncol. 2002; 20: 3199–3205. PMID: 12149291

13. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004; 58: 862–870. PMID: 14967443

14. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012; 366: 925–931. doi: 10.1056/NEJMoa1112824 PMID: 23397654

15. Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 70: 1124–1129. doi: 10.1016/j.ijrobp.2007.01.044 PMID: 18313526

16. Boeinger D, Maingon P, Poormans T, Baron MH, Mirlalbell R, Remouchamps V, et al. Guidelines for primary radiotherapy of patients with prostate cancer. Radiother Oncol. 2006; 79: 259–269. PMID: 16797094

17. McGrath SD, Antonucci JV, Fitch DL, Ghilezan M, Gustafson GS, Vicini FA, et al. PSA bounce after prostate brachytherapy with or without neoadjuvant androgen deprivation. Brachytherapy. 2010; 9: 137–144. doi: 10.1016/j.brachy.2009.07.005 PMID: 19850537

18. Suzman DL, Antonarakis ES. Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol. 2014; 6: 167–179. doi: 10.1177/1758834014529176 PMID: 25057303

19. Camphausen K, Moses MA, Beecken WD, Khan MK, Folkman J, O’Reilly MS. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res. 2001; 61: 2207–2211. PMID: 11280788

20. Morgan SC, Parker CC. Local treatment of metastatic cancer—killing the seed or disturbing the soil? Nat Rev Clin Oncol. 2011; 8: 504–506. doi: 10.1038/nrclinonc.2011.88 PMID: 21647193
21. Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005; 438: 820–827. PMID: 16341007

22. Weckermann D, Polzer B, Ragg T, Biana A, Schlimok G, Arnholdt H, et al. Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol. 2009; 27: 1549–1556. doi: 10.1200/JCO.2008.17.0563 PMID: 19237635

23. Engel J, Bastian PJ, Baur H, Beer V, Chaussy C, Gschwend JE, et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol. 2010; 57: 754–761. doi: 10.1016/j.eururo.2009.12.034 PMID: 20106588

24. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1502–1512. PMID: 15470213

25. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010; 363: 411–422. doi: 10.1056/NEJMoia1001294 PMID: 20818862

26. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711–723. doi: 10.1056/NEJMoia1003466 PMID: 20525992

27. Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, et al. High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys. 2002; 53: 1111–1116. PMID: 12128109

28. Lee IJ, Seong J, Lee CG, Kim YB, Keum KC, Suh CO, et al. Early clinical experience and outcome of helical tomotherapy for multiple metastatic lesions. Int J Radiat Oncol Biol Phys. 2009; 73: 1517–1524. doi: 10.1016/j.ijrobp.2008.07.035 PMID: 19084348

29. Gandaglia G, Karakiewicz PI, Briganti A, Passoni NM, Schillhammer J, Trudeau V, et al. Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer. Eur Urol. 2015; 68: 325–334. doi: 10.1016/j.eururo.2014.07.020 PMID: 25108577

30. Staehler MD, Kruse J, Haseke N, Stadler T, Roosen A, Karl A, et al. Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis. World J Urol. 2010; 28: 543–547. doi: 10.1007/s00345-010-0560-4 PMID: 20440505

31. Nguyen DH, Truong PT, Walter CV, Hayashi E, Christie JL, Alexander C. Limited M1 disease: a significant prognostic factor for stage IV breast cancer. Ann Surg Oncol. 2012; 19: 3028–3034. doi: 10.1245/s10434-012-2333-3 PMID: 22476751

32. Parker CC, Sydes MR, Mason MD, Clarke NW, Aebersold D, de Bono JS, et al. Prostate radiotherapy for men with metastatic disease: a new comparison in the Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE) trial. BJU Int. 2013; 111: 697–699. doi: 10.1111/bju.12087 PMID: 23578233